MY110517A - Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present. - Google Patents
Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present.Info
- Publication number
- MY110517A MY110517A MYPI92001379A MYPI19921379A MY110517A MY 110517 A MY110517 A MY 110517A MY PI92001379 A MYPI92001379 A MY PI92001379A MY PI19921379 A MYPI19921379 A MY PI19921379A MY 110517 A MY110517 A MY 110517A
- Authority
- MY
- Malaysia
- Prior art keywords
- group
- substituted
- alkyl
- alkyls
- free
- Prior art date
Links
- 125000003368 amide group Chemical group 0.000 title 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 BENZYLOXY GROUP Chemical group 0.000 abstract 38
- 150000002367 halogens Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 abstract 1
- SNPQRYOQWLOTFA-UHFFFAOYSA-N 2,2-dimethyl-1,3-thiazolidine Chemical compound CC1(C)NCCS1 SNPQRYOQWLOTFA-UHFFFAOYSA-N 0.000 abstract 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000001925 cycloalkenes Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
THE INVENTION RELATES TO COMPOUNDS OF FORMULA(FORMULA I)IN WHICH -R1 IS A HALOGEN ATOM, A C1-C4 ALKYL, A HYDROXYL, A C1-C4 ALKOXY, A BENZYLOXY GROUP, A CYANO GROUP, A TRIFLUOROMETHYL GROUP, NITRO GROUP OR AN AMINO GROUP; -R2 IS A C1-C6 ALKYL, A C3-C7 CYCLOALKYL, A C5-C7 CYCLOALKENE OR A PHENYL WHICH IS UNSUBSTITUTED OR MONOSUBSTITUTED OR POLYSUBSTITUTED BY A C1-C4 ALKYL, A C1-C4 ALKOXY, A HALOGEN, A TRIFLUOROMETHYL GROUP OR AN AMINO GROUP, OR R2 IS NITROPHENYL WHICH IS UNSUBSTITUTED OR MONOSUBSTITUTED BY A TRIFLUOROMETHYL GROUP OR MONOSUBSTITUTED OR POLYSUBSTITUTED BY A C1-C4 ALKYL OR A HALOGEN; -R3 IS A HYDROGEN ATOM; -R4 IS A CARBAMOYL GROUP OF FORMULA CONR6R7; -R5 IS A C1-C4 ALKYL; A 1-NAPTHTYL; A 2-NAPTHYL; A 5-DIMETHYLAMINO-1-NAPHTHYL; A PHENYL WHICH IS UNSUBSTITUTED OR SUBSTITUTED BY ONE OR MORE SUBSTITUENTS SELECTED FROM A HALOGEN ATOM, A C1-C4 ALKYL, A TRIFLUOROMETHYL GROUP, AN AMINO GROUP WHICH IS FREE OR SUBSTITUTED BY ONE OR 2 C1-C4 ALKYLS, A HYDROXYL, A C1-C4 ALKOXY, A C2-C4 ALKENOXY, A C1-C4 ALKYLTHIO, A TRIFLUOROMETHOXY GROUP, A BENZYLOXY GROUP, A CYANO GROUP, A CARBOXYL GROUP, A C1-C4 ALKOXYCARBONYL GROUP, A CARBAMOYL GROUP WHICH IS FREE OR SUBSTITUTED BYONE OR TWO C1-C4 ALKYLS OR A C1-C4 ALKYLAMIDO GROUP, OR R5 IS A NITROPHENYL WHICH IS UNSUBSTITUTED OR MONOSUBSTITUTED BY A TRIFLUOROMETHYL GROUP OR A C2-C4 ALKENOXY OR MONO- OR POLY-SUBSTITUTED BY AHALOGEN, A C1-C4 ALKYL, A C1-C4 ALKOXY, A C1-C4 ALKYLTHIO, A TRIFLUOROMETHOXY GROUP OR A BENZYLOXY GROUP; -R6 IS A C1-C6 ALKYL OR R6 IS SIMILAR TO R7; -R7 IS A 4-PIPERIDYL GROUP OR A 3-AZETIDINYL GROUP, THE SAID GROUPS BEING SUBSTITUTED OR UNSUBSTITUTED ON THE NITROGEN BY A C1-C4 ALKYL, BY A BENZYLOXYCARBONYL OR BY A C1-C4 ALKOXYCARBONYL; A GROUP (CH2)R WHICH IS ITSELF SUBSTITUTED BY A 2-, 3- OR 4- PYRIDYL GROUP, BY A HYDROXYL GROUP OR BY AN AMINO GROUP WHICH IS FREE OR SUBSTITUTED BY ONE OR TWO C1-C4 ALKYLS, A CARBOXYL GROUP, A C1-C4 ALKOXYCARBONYL GROUP, A BENZYLOXYCARBONYL GROUP OR A CA RBAMOYL GROUP WHICH IS FREE OR SUBSTITUTED BY ONE OR 2 C1-C4 ALKYLS; OR R6 AND R7 TOGETHER, WITH THE NITROGEN ATOM TO WHICH THEY ARE CONNECTED, FORM A HETEROCYCLE SLECTED FROM: . MORPHOLINE, . THIOMORPHOLINE, . THIAZOLIDINE OR 2, 2-DIMETHYLTHIAZOLIDINE, UNSUBSTITUTED OR SUBSTITUTED BY R8 . PIPERAZINE, UNSUBSTITUTED OR SUBSTITUTED AT THE 4-POSITION BY A GROUP R''''8, . AN UNSATURATED, 5-MEMBERED RING CONTAINING A SINGLE NITROGEN ATOM AND SUBSTITUTED BY R8 OR A SATURATED, 3-, 4-, 6- OR 7-MEMBERED RING CONTAINING A SINGLE NITROGEN ATOM AND SUBSTITUTED BY R8 AND R9; -R8 IS R''8 OR A GROUP (CH2)R WHICH ITSELF SUBSTITUTED BY A HYDROXYL OR BY AN AMINO WHICH IS FREE OR SUBSTITUTED BY ONE OR 2 C1-C4 ALKYLS; -R''8 IS A GROUP (CH2)Q WHICH IS ITSELF SUBSTITUTED BY A CARBOXYL GROUP, A C1-C4 ALKOXYCARBONYL GROUP, A BENZYLOXYCARBONYL GROUP, A CARBAMOYL GROUP WHICH IS FREE OR SUBSTITUTED BY A HYDROXYL OR BY ONE OR 2 C1-C4 ALKYLS OR AN AMINOCARBOTHIOYL GROUP WHICH IS FREE OR SUBSTITUTED BY ONE OR 2 C1-C4 ALKYLS; -R''''8 IS R''8 OR A GROUP (CH2)2NH2 WHICH IS FREE OR SUBSTITUTED BY ONE OR TWO C1-C4 ALKYLS; -R9 IS HYDROGEN, A HALOGEN, A GROUP (CH2)ROR10, A GROUP (CH2)RNR11R12, A GROUP (CH2)SCONR11R''11 OR AN AZIDO GROUP; -R10 IS HYDROGEN , A C1-C4 ALKYL, A MESYL OR A TOSYL; -R11, R''11 AND R12 ARE EACH HYDROGEN OR A C1-C4 ALKYL OR R11 IS HYDROGEN AND R12 IS A BENZYLOXYCARBONYL OR A C1-C4 ALKOXYCARBONYL; -N IS O, 1, 2 OR 3; -M IS 0, 1 OR 2; -Q IS 0,1,2 OR 3; -R IS O,1,2 OR 3, WITH THE LIMITATION THAT R IS NOT ZERO WHEN R8 OR R9 IS AT THE ALPHA-POSITION OF THE INTRACYCLIC AMIDE NITROGEN; -S ISO OR 1; AS WELL AS ITS POSSIBLE SALTS. THESE COMPOUNS ARE USEFUL IN THE TREATMENT OF COMPLAINTS OF THE CENTRAL NERVOUS SYSTEM AND THE GASTRIC SPHERE IN HUMANS AND ANIMALS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9109908A FR2679903B1 (en) | 1991-08-02 | 1991-08-02 | DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY110517A true MY110517A (en) | 1998-07-31 |
Family
ID=9415909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI92001379A MY110517A (en) | 1991-08-02 | 1992-07-31 | Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present. |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0526348B1 (en) |
| JP (1) | JP2633085B2 (en) |
| KR (1) | KR100241583B1 (en) |
| AT (1) | ATE163289T1 (en) |
| AU (2) | AU658664B2 (en) |
| BR (1) | BR9205336A (en) |
| CA (2) | CA2206776C (en) |
| CZ (1) | CZ288173B6 (en) |
| DE (1) | DE69224450T2 (en) |
| DK (1) | DK0526348T3 (en) |
| ES (1) | ES2117038T3 (en) |
| FI (2) | FI104069B1 (en) |
| FR (1) | FR2679903B1 (en) |
| HK (1) | HK1008741A1 (en) |
| HU (2) | HUT68927A (en) |
| IL (3) | IL117592A (en) |
| LT (1) | LT3064B (en) |
| LV (1) | LV10091B (en) |
| MX (1) | MX9204487A (en) |
| MY (1) | MY110517A (en) |
| NO (1) | NO180047C (en) |
| NZ (1) | NZ243795A (en) |
| PH (1) | PH30661A (en) |
| RU (1) | RU2104268C1 (en) |
| SG (1) | SG47501A1 (en) |
| SK (1) | SK283463B6 (en) |
| UA (1) | UA27238C2 (en) |
| WO (1) | WO1993003013A1 (en) |
| ZA (1) | ZA925781B (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665441B1 (en) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
| FR2708608B1 (en) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them. |
| FR2756736B1 (en) * | 1996-12-05 | 1999-03-05 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES |
| US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| HUP0003921A3 (en) * | 1997-07-31 | 2001-03-28 | Wyeth Corp | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
| EP1001971A1 (en) * | 1997-07-31 | 2000-05-24 | Elan Pharmaceuticals, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| WO1999006433A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| FR2775598A1 (en) | 1998-03-06 | 1999-09-10 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS |
| FR2778103A1 (en) * | 1998-04-29 | 1999-11-05 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST |
| FR2786486B3 (en) * | 1998-11-16 | 2000-12-08 | Sanofi Sa | PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES |
| PL350050A1 (en) | 1999-01-22 | 2002-10-21 | Elan Pharm Inc | Acyl derivatives which treat vla-4 related disorders |
| IL143928A0 (en) | 1999-01-22 | 2002-04-21 | Elan Pharm Inc | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| MXPA01007394A (en) * | 1999-01-25 | 2002-04-09 | Wyeth Corp | Compounds which inhibit leukocyte adhesion mediated by vla-4. |
| US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| GB9902461D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| FR2792834A1 (en) * | 1999-04-29 | 2000-11-03 | Sanofi Sa | USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON |
| FR2805536B1 (en) | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2805992A1 (en) * | 2000-03-08 | 2001-09-14 | Sanofi Synthelabo | Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability |
| EP1335901B1 (en) | 2000-10-17 | 2010-04-14 | Merck Serono SA | Pharmaceutically active sulfanilide derivatives |
| CA2425892A1 (en) | 2000-11-28 | 2003-04-11 | Hiroyuki Koshio | 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof |
| JP4044740B2 (en) * | 2001-05-31 | 2008-02-06 | 信越化学工業株式会社 | Resist material and pattern forming method |
| US7468385B2 (en) | 2001-12-20 | 2008-12-23 | Laboratoires Serono Sa | Triazoles as oxytocin antagonists |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| EP2399903A1 (en) * | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| ES2311721T3 (en) * | 2002-09-17 | 2009-02-16 | F. Hoffmann-La Roche Ag | INDOLES REPLACED IN POSITION 2.4 AND ITS USE AS MODULATORS OF 5-HT6. |
| MXPA05002696A (en) * | 2002-09-17 | 2005-05-05 | Hoffmann La Roche | 2,7-substituted indoles and their use as 5-ht6 modulators. |
| US7279578B2 (en) * | 2002-10-11 | 2007-10-09 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic acid derivatives |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| CN101048376B (en) * | 2004-10-27 | 2011-03-23 | 橘生药品工业株式会社 | Indoline compound and process for producing the same |
| ATE493405T1 (en) | 2005-09-29 | 2011-01-15 | Elan Pharm Inc | PYRIMIDINYLAMIDE COMPOUNDS THAT INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 |
| CA2624524C (en) | 2005-09-29 | 2014-07-08 | Elan Pharmaceuticals, Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
| WO2007101165A1 (en) | 2006-02-27 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| AU2010241742A1 (en) | 2009-04-27 | 2011-11-17 | Elan Pharmaceuticals, Inc. | Pyridinone antagonists of alpha-4 integrins |
| TW201938171A (en) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | Tricyclic compounds as vasopressin V1a receptor antagonists |
| HU231206B1 (en) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepines |
| TW202542165A (en) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | Macrocyclic orexin agonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3838167A (en) * | 1972-08-01 | 1974-09-24 | Lilly Co Eli | Process for preparing indoles |
| US4479963A (en) * | 1981-02-17 | 1984-10-30 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
| DE3705934A1 (en) * | 1987-02-25 | 1988-09-08 | Nattermann A & Cie | Indolyl derivatives, processes for their preparation, and their use as medicaments |
| FR2665441B1 (en) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
-
1991
- 1991-08-02 FR FR9109908A patent/FR2679903B1/en not_active Expired - Fee Related
-
1992
- 1992-07-31 UA UA93002340A patent/UA27238C2/en unknown
- 1992-07-31 IL IL11759292A patent/IL117592A/en not_active IP Right Cessation
- 1992-07-31 LV LVP-92-87A patent/LV10091B/en unknown
- 1992-07-31 MY MYPI92001379A patent/MY110517A/en unknown
- 1992-07-31 CA CA002206776A patent/CA2206776C/en not_active Expired - Fee Related
- 1992-07-31 PH PH44760A patent/PH30661A/en unknown
- 1992-07-31 BR BR9205336A patent/BR9205336A/en not_active Application Discontinuation
- 1992-07-31 ZA ZA925781A patent/ZA925781B/en unknown
- 1992-07-31 CZ CZ1993682A patent/CZ288173B6/en not_active IP Right Cessation
- 1992-07-31 CA CA002093221A patent/CA2093221C/en not_active Expired - Fee Related
- 1992-07-31 RU RU93005168A patent/RU2104268C1/en not_active IP Right Cessation
- 1992-07-31 HU HU9300951A patent/HUT68927A/en unknown
- 1992-07-31 SK SK426-93A patent/SK283463B6/en unknown
- 1992-07-31 WO PCT/FR1992/000758 patent/WO1993003013A1/en not_active Ceased
- 1992-07-31 KR KR1019930701034A patent/KR100241583B1/en not_active Expired - Fee Related
- 1992-07-31 AU AU24758/92A patent/AU658664B2/en not_active Ceased
- 1992-07-31 JP JP5503337A patent/JP2633085B2/en not_active Expired - Fee Related
- 1992-07-31 IL IL102703A patent/IL102703A/en not_active IP Right Cessation
- 1992-07-31 MX MX9204487A patent/MX9204487A/en not_active IP Right Cessation
- 1992-07-31 NZ NZ243795A patent/NZ243795A/en unknown
- 1992-07-31 LT LTIP114A patent/LT3064B/en not_active IP Right Cessation
- 1992-08-03 SG SG1996002367A patent/SG47501A1/en unknown
- 1992-08-03 AT AT92402213T patent/ATE163289T1/en not_active IP Right Cessation
- 1992-08-03 DE DE69224450T patent/DE69224450T2/en not_active Expired - Fee Related
- 1992-08-03 DK DK92402213T patent/DK0526348T3/en active
- 1992-08-03 EP EP92402213A patent/EP0526348B1/en not_active Expired - Lifetime
- 1992-08-03 ES ES92402213T patent/ES2117038T3/en not_active Expired - Lifetime
-
1993
- 1993-04-01 FI FI931476A patent/FI104069B1/en not_active IP Right Cessation
- 1993-04-01 NO NO931262A patent/NO180047C/en not_active IP Right Cessation
-
1995
- 1995-02-03 AU AU11541/95A patent/AU691223B2/en not_active Ceased
- 1995-06-28 HU HU95P/P00474P patent/HU211884A9/en unknown
-
1996
- 1996-03-21 IL IL11759296A patent/IL117592A0/en unknown
-
1998
- 1998-01-27 FI FI980175A patent/FI107048B/en not_active IP Right Cessation
- 1998-07-03 HK HK98108861A patent/HK1008741A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY110517A (en) | Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present. | |
| FR2673427B1 (en) | N-SUBSTITUTED DIAZOTATED HETEROCYCLIC DERIVATIVES BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| IL99012A0 (en) | N-sulfonylindoline derivatives,their preparation and pharmaceutical compositions containing them | |
| CY1108913T1 (en) | DERIVATIVE 4 (FENYL-PIPERAZYNYL-METHYL) BENZAMIDIUM AND THEIR USE FOR THERAPEUTIC TREATMENT OF PAIN, AGHTRA GASTR | |
| NO932326L (en) | hydroxamic acid derivatives | |
| ATE164837T1 (en) | ACETAMIDE DERIVATIVES AND THEIR USE AS DIGESTIVE BEHAVIOR MODIFIERS | |
| DK0382687T3 (en) | N-Containing heterocyclic derivatives having an undensified benzene ring | |
| NO920035L (en) | TRIFLUORMETHYLKETON DERIVATIVES AND THEIR PREPARATION AND USE | |
| HUP9901630A2 (en) | Novel indole-2,3-dione-3-oxime derivatives | |
| GB1058984A (en) | Indolyl amides | |
| ATE168672T1 (en) | INDOLE-PIPERAZINE DERIVATIVES AS SELECTIVE LIGANDS OF THE 5HT1D AND 5HT1B RECEPTORS USABLE AS MEDICINAL PRODUCTS | |
| DE69502333D1 (en) | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions and uses containing them | |
| SE8101464L (en) | 2-PENEM-3-CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE | |
| IL127177A (en) | ANTIPYSYCHOTIC 5-(1, 3, 4, 4a, 5, 9b-HEXAHYDRO-PYRIDO (3, 4-b) INDOL-2-YLALKYL) PYRIMIDIN-4-ONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DE69202166D1 (en) | Use of tetrahydrothienopyridine derivatives as angiogenesis inhibitors. | |
| ES433959A1 (en) | PROCEDURE FOR THE PREPARATION OF NEW DERIVATIVES OF ISOQUINOLEIN. | |
| ES417638A1 (en) | PROCEDURE TO PREPARE 2,4,5-TRISUSTITUED OXAZOLES. | |
| HUP9900914A2 (en) | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation | |
| ATE144497T1 (en) | N-SUBSTITUTED 3-AZABICYCLO(3.2.0>HEPTANDE DERIVATIVES AS NEUROLEPTICS | |
| PT827500E (en) | (2-MORFOLINYLMETHYL) BENZAMIDE DERIVATIVES | |
| ES412050A1 (en) | Procedure for preparation of benzodioxolo derivatives. (Machine-translation by Google Translate, not legally binding) | |
| NO860046L (en) | 5-ARYL-DIHYDROPYRIDINES, PROCEDURES FOR THEIR PREPARATION, AND THEIR USE IN PHARMACEUTICALS. | |
| RU96121821A (en) | PURIN-6-ONE DERIVATIVES, THEIR TOUTOMERS AND SALTS, PHARMACEUTICAL COMPOSITION WITH ACTIVITY OF KHMP ACTIVITY |